Answers are grounded in this paper and cite their sources.
Analysis reveals no survival benefits of sotorasib in colorectal cancer, highlighting concerns in trial methodology.
Although no survival benefit over standard therapies has been established, the combination of sotorasib plus panitumumab recently received full US Food and Drug Administration approval for use in advanced colorectal cancer. The authors highlight key concerns with the CodeBreaK 300 trial design, conduct, and reporting, arguing that excitement for precision medicines must be matched by methodological rigor and transparent reporting.
No takes yet. Share an insight, caveat, or question.
Stevens et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: